Abstract
ObjectiveOur purpose was to assess the effect of ligustrazine in the prevention of contrast-induced nephropathy (CIN) in patients with unstable angina (UA).Methods148 patients with UA undergoing coronary angiography and/or percutaneous coronary intervention (PCI) were selected for observation; the patients were divided into a control group (group A, n=74) and a ligustrazine group (group B, n=74). Group A was given routine treatment, while group B was given routine treatment combined with ligustrazine. Serum creatinine (Scr), cystatin C and glomerular filtration rate (eGFR) concentrations were measured before and 1 day, 2 days and 3 days after treatment, and the incidence of contrast-induced nephropathy (CIN) and major cardiovascular events (MACE) were observed in both groups.ResultsThe Scr, Cystatin C and eGRF levels in group B were better than in group A after 1 day (OR: 2.64, 95% CI: 2.47-4.98; OR: 2.66, 95% CI: 2.62-5.77; OR: 4.02, 95% CI: 3.02-5.53, respectively), 2 days (OR: 3.58, 95% CI: 2.41-4.92; OR: 2.92, 95% CI: 2.83-5.02; OR: 3.28, 95% CI: 3.24-5.14, respectively) and 3 days of treatment (OR: 3.26, 95% CI: 2.17-4.35; OR: 2.85, 95% CI: 2.26-4.02; OR: 3.19, 95% CI: 2.53-4.34, respectively). The incidence of CIN (9.26% vs 16.67%) and MACE (7.41% vs 18.51%) of group B were significantly lower than in group A (P<0.05).ConclusionsOur study suggests that ligustrazine can reduce CIN and MACE in patients with UA when undergoing coronary angiography and/or PCI.
Highlights
Contrast-induced nephropathy (CIN) [1, 2, 3] is an acute renal function injury that occurs within 3 days after using contrast agent when excluding other factors that may damage renal function
Our study suggests that ligustrazine can reduce CIN and major cardiovascular events (MACE) in patients with unstable angina (UA) when undergoing coronary angiography and/or percutaneous coronary intervention (PCI)
After adjusting for smoking, previous myocardial infarction (MI), albumin, HDL-C, iodixanol dosage, ACEIs/ARBs, beta-blockers and GPIIb/IIIa inhibitors, the Serum creatinine (Scr), Cystatin C and eGRF levels in group B were better than in group A after 1 day of treatment (OR: 2.64, 95% CI: 2.47-4.98; OR: 2.66, 95% CI: 2.62-5.77; OR: 4.02, 95% CI: 3.02-5.53, respectively)
Summary
Contrast-induced nephropathy (CIN) [1, 2, 3] is an acute renal function injury that occurs within 3 days after using contrast agent when excluding other factors that may damage renal function. In hospital-acquired acute kidney injury, CIN has become the third major cause of renal perfusion decrease and renal drug toxicity [4, 5]. Previous research results have shown that in patients who receive contrast agents, the incidence of CIN is approximately 1%-6% [8]. Once CIN has occurred, hospitalization time is longer, and the cost of health care increases, presenting a considerable economic burden to society. Because no effective measure for the treatment of CIN has been developed, research for CIN is primarily focused on prevention
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
